Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibuprofen + chlorpheniramine + phenylephrine
- Development stage
- Discontinued
- Lead developer
- EMS
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Irlanda-2-Association** is a fixed-dose oral combination product containing **ibuprofen**, **chlorpheniramine**, and **phenylephrine**, developed by **EMS** for symptomatic treatment of the **common cold**. Based on the provided clinical trial record, the name appears to be a study-specific or product-specific label for this three-drug combination rather than a distinct new molecular entity. The combination pairs a nonsteroidal anti-inflammatory drug for pain, fever, and inflammatory symptoms, an H1 antihistamine for rhinorrhea and sneezing, and an alpha-1 adrenergic agonist decongestant for nasal congestion. It is therefore best characterized as a multi-ingredient symptomatic cold medication rather than a novel single-agent therapeutic.
- Brand names
- Irlanda-2Irlanda2Irlanda 2
- Other names
- Irlanda-2-AssociationIrlanda2-AssociationIrlanda 2-Associationibuprofen + chlorpheniramine + phenylephrine
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)ADRA1A (α1A)
Beyond the preview
Go deeper on ibuprofen + chlorpheniramine + phenylephrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibuprofen + chlorpheniramine + phenylephrine.